Predicting lifetime cardiovascular risk and benefits of preventive treatment in patients with established atherosclerotic cardiovascular disease: the SMART-REACH2 model
Listen to this summary
The authors aimed to develop the SMART-REACH2 model to estimate the lifetime risk of recurrent cardiovascular (CV) events and the benefits of preventive treatment in patients with established atherosclerotic CV disease, incorporating geographical and sex-specific variations. The model was validated in a large cohort and demonstrated adequate performance across different risk regions, providing insights into potential gains in CV disease-free life expectancy with intensified treatment. This tool aims to enhance shared decision-making in clinical practice as recommended by current guidelines.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from European heart journal
View all →Jun 11, 2026 · European heart journal
Accelerated epigenetic ageing in congenital heart disease: the AccelerAGE study
Jun 9, 2026 · European heart journal
Statins and survival free of incident frailty among older US veterans
Jun 5, 2026 · European heart journal
Extracellular vesicles in atherosclerotic cardiovascular disease: mechanisms and therapeutic implications
Jun 5, 2026 · European heart journal
P2Y12 inhibitor monotherapy after abbreviated dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis
Jun 5, 2026 · European heart journal
ACADM-mediated fatty acid β-oxidation pathway in atherosclerosis and abdominal aortic aneurysm
Jun 5, 2026 · European heart journal
RNA splicing and cardiovascular disease: a guide for cardiologists
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
